Iravani, M. M. Et Al. 2008. Continuous subcutaneous infusion of pramipexole protects against lipopolysaccharide-induced dopaminergic cell death without affecting the inflammatory response. EXPERIMENTAL NEUROLOGY , vol.212, no.2 , 522-531.

Iravani, M. M., Sadeghian, M., Leung, C., TEL, B. C., Rose, S., Schapira, A. H., ... Jenner, P.(2008). Continuous subcutaneous infusion of pramipexole protects against lipopolysaccharide-induced dopaminergic cell death without affecting the inflammatory response. EXPERIMENTAL NEUROLOGY , vol.212, no.2, 522-531.

Iravani, Mahmoud Et Al. "Continuous subcutaneous infusion of pramipexole protects against lipopolysaccharide-induced dopaminergic cell death without affecting the inflammatory response," EXPERIMENTAL NEUROLOGY , vol.212, no.2, 522-531, 2008

Iravani, Mahmoud M. Et Al. "Continuous subcutaneous infusion of pramipexole protects against lipopolysaccharide-induced dopaminergic cell death without affecting the inflammatory response." EXPERIMENTAL NEUROLOGY , vol.212, no.2, pp.522-531, 2008

Iravani, M. M. Et Al. (2008) . "Continuous subcutaneous infusion of pramipexole protects against lipopolysaccharide-induced dopaminergic cell death without affecting the inflammatory response." EXPERIMENTAL NEUROLOGY , vol.212, no.2, pp.522-531.

@article{article, author={Mahmoud M Iravani Et Al. }, title={Continuous subcutaneous infusion of pramipexole protects against lipopolysaccharide-induced dopaminergic cell death without affecting the inflammatory response}, journal={EXPERIMENTAL NEUROLOGY}, year=2008, pages={522-531} }